Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KH801 in Advanced Solid Tumors
NCT06364501Phase 1Not yet recruiting
- Sponsor
- Beijing Kanghong Biopharmaceutical
- Start
- Sep 2024
- Primary completion
- May 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of KH-801 in solid tumor (advanced stage), sponsored by Beijing Kanghong Biopharmaceutical. Primary endpoints: Maximum Tolerated Dose up to 4 weeks, Dose Limiting Toxicity up to 4 weeks and 1 more. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
KH-801
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06364501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06364501.